Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies GlobeNewswire December 08, 2025 Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically meaningful functional improvements (p less-than or equal to 0.002) Patients […]